Article Text

Download PDFPDF

The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities
  1. Pia Bjorck1,
  2. Erin Filbert1,
  3. Yongke Zhang1,
  4. Xiaodong Yang1 and
  5. Ovid Trifan1
  1. Aff1 Apexigen, Inc. San Carlos CA USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

The co-stimulatory receptor CD40 is a member of the tumor necrosis factor receptor (TNFR) superfamily and plays an important role in the control and regulation of immune activation, especially in crosstalk between T cells and antigen presenting cells (APCs). The natural ligand for CD40 (CD40L, CD154) is expressed on activated T cells and provides a major component of T cell “help” for the immune response. Agonistic CD40 antibodies can substitute for the function of CD154 on T cells to boost immunity by stimulating antigen presentation and co-stimulation to T cells and have been shown to be potent boosters of anti-tumor immune responses. Anti-CD40 can directly inhibit tumor growth in CD40 expressing tumor cells.

APX005M is a humanized IgG1 monoclonal antibody that binds CD40 with high affinity and blocks the binding of CD40 to CD40L. APX005M activates dendritic cells, B cells and monocytes, and promotes antigen-specific T cell responses. APX005M demonstrates potent anti-tumor activity via ADCC and induction of apoptosis in CD40 expressing tumor cells. In comparison with other CD40 agonistic antibodies such as CP-870, 893 and SGN-40 analogs, APX005M has more potent CD40 agonistic effects and antibody effector function.